We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look ...

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Dividend stocks have remained a popular choice among investors due to the steady income they provide, becoming even more ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain.

Representative Julie Johnson (D-Texas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 12th, the Representative disclosed that they had sold between $1,001 and $15,000 ...

If you are looking for an AI stock that is more promising than PFE but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

Xponance Inc. grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 4.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The ...

I confirm my "Buy" rating because I believe PFE has got a bigger upside than last year, although its stock price basically stayed flat. Analyst’s Disclosure: I/we have a beneficial long position ...